Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Asset Writedowns and Impairment: 2018-2022

Historic Asset Writedowns and Impairment for Organogenesis Holdings (ORGO) over the last 5 years, with Dec 2022 value amounting to -$855,000.

  • Organogenesis Holdings' Asset Writedowns and Impairment fell 235.28% to -$855,000 in Q4 2022 from the same period last year, while for Sep 2022 it was $1.5 million, marking a year-over-year increase of 50.51%. This contributed to the annual value of $18.8 million for FY2024, which is N/A change from last year.
  • As of Q4 2022, Organogenesis Holdings' Asset Writedowns and Impairment stood at -$855,000, which was down 216.64% from $733,000 recorded in Q3 2022.
  • In the past 5 years, Organogenesis Holdings' Asset Writedowns and Impairment ranged from a high of $1.6 million in Q3 2020 and a low of -$1.4 million during Q4 2020.
  • Its 3-year average for Asset Writedowns and Impairment is $348,250, with a median of $603,500 in 2021.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first surged by 2,937.50% in 2020, then slumped by 235.28% in 2022.
  • Quarterly analysis of 5 years shows Organogenesis Holdings' Asset Writedowns and Impairment stood at $1.2 million in 2018, then crashed by 119.38% to -$56,000 in 2019, then surged by 2,937.50% to -$1.4 million in 2020, then soared by 145.93% to $632,000 in 2021, then slumped by 235.28% to -$855,000 in 2022.
  • Its Asset Writedowns and Impairment stands at -$855,000 for Q4 2022, versus $733,000 for Q3 2022 and $82,000 for Q2 2022.